Catabasis Pharmaceuticals (NASDAQ: CATB) and Celgene (NASDAQ:CELG) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.
This table compares Catabasis Pharmaceuticals and Celgene’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Volatility and Risk
Catabasis Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Celgene has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.
This is a summary of recent recommendations for Catabasis Pharmaceuticals and Celgene, as provided by MarketBeat.com.
||Strong Buy Ratings
Catabasis Pharmaceuticals currently has a consensus price target of $5.67, indicating a potential upside of 509.84%. Celgene has a consensus price target of $124.13, indicating a potential upside of 61.84%. Given Catabasis Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Catabasis Pharmaceuticals is more favorable than Celgene.
Institutional & Insider Ownership
26.8% of Catabasis Pharmaceuticals shares are held by institutional investors. Comparatively, 75.5% of Celgene shares are held by institutional investors. 32.3% of Catabasis Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Celgene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Catabasis Pharmaceuticals and Celgene’s top-line revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Celgene has higher revenue and earnings than Catabasis Pharmaceuticals. Catabasis Pharmaceuticals is trading at a lower price-to-earnings ratio than Celgene, indicating that it is currently the more affordable of the two stocks.
Celgene beats Catabasis Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. to advance a PD-1 Inhibitor program for solid tumor cancers. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; and Prothena Corporation plc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.